Metformin in Diabetic Patients with Heart Failure: Safe and Effective? - Wikidata - wikimedia - TriplyDB

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

http://www.wikidata.org/entity/Q37508043

about

Remodeling of glucose metabolism precedes pressure overload-induced left ventricular hypertrophy: review of a hypothesis.The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure Metformin as a cellular protector; a synoptic view of modern evidences Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 Diabetes Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure.

P2860

Q26853332-9D1EF9AC-899E-4C2F-844A-638F46FEE21B Q28082343-E5728460-AEB5-4AC4-9E9F-D78123C5D124 Q28817196-98ADAAB9-0472-4446-9374-695A12AC60BE Q33815573-186BBC60-2E0A-4B52-8DA7-BF923B2E7CD6 Q37134345-24F3BA37-CB8F-407C-BA35-92EA1AF4E6EA Q38829782-F568356C-3762-46CE-9CF2-CA75461969D9 Q39396845-203D58FA-36FA-47F0-8304-D8D3A88FA080

P2860

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

http://www.wikidata.org/entity/Q37508043

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

@en

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

@nl

type

label

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

@en

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

@nl

prefLabel

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

@en

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

@nl

P1433

Q37508043-5E18D8E1-2E0A-4640-B9D2-99A0D11D75A0

P1476

Q37508043-BE4BFF3F-EF5E-40A6-82E3-C4D59175EA6B

P2093

Q37508043-C3FC43F7-BBFE-4DD9-8F75-CE21DE0EAD02

Q37508043-CBEA3405-6EBE-45F3-B721-ECEE7264A51F

Q37508043-D0F3CFA7-C629-4FF4-9722-FFEAFBA19EDF

P2860

Q37508043-033B0BAB-D2C8-4BC1-940F-EA0A1CDAE544

Q37508043-0A55635B-AE77-478E-B219-271DCCA12688

Q37508043-0BEE3E74-5F9A-4F33-B51C-DDE35CF0FF6F

Q37508043-102DEB21-D0FF-4F4A-9A1A-4551276EBC96

Q37508043-14006487-F7F1-4394-9C4E-77CDF91FFF85

Q37508043-194A2609-1E10-4A95-9DAD-EFDFBCF8265D

Q37508043-1F3958C5-E2FF-4E90-BF2B-F57C0EE636C6

Q37508043-23B6FA8E-B2A0-46E0-806E-55AF25DC74AD

Q37508043-24129012-92AE-4E0A-961C-816102B37EC5

Q37508043-26E73DE3-BC65-4358-B8FE-941E9AD5CA82

P2888

Q37508043-27417FE9-D9D0-4183-8D7A-942BCA5AE632

P304

Q37508043-72BA5B1E-9751-4489-9403-F14369E39B7A

P31

Q37508043-DD1A4D94-E2D4-4058-81BC-E3886623B4F1

P356

Q37508043-0DBA3880-CE9B-4EB1-9606-D56FBB985068

P433

Q37508043-BA000140-ACA7-472E-A2AC-F97B30015792

P478

Q37508043-8E45CE7A-569F-486E-903B-3BABF7753C9E

P577

Q37508043-07049394-CF7C-430F-87F9-A6A3524B4C91

P698

Q37508043-2C6CF127-83E9-403A-A0C0-61062C5F93A0

P921

Q37508043-7B6B873B-8B2D-4C25-98CF-0765A7B84B64

Q37508043-ADEFB91F-8A57-455F-9B74-CE84DEAEA578

P932

Q37508043-F934DAB6-DA5C-46A1-8DCF-F30D5F193C59

P356

S12170-013-0355-4

P1433

Current cardiovascular risk reports

P1476

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

@en

P2093

Amirreza Solhpour

http://www.w3.org/2001/XMLSchema#string

Heinrich Taegtmeyer

http://www.w3.org/2001/XMLSchema#string

Ijeoma Ananaba Ekeruo

http://www.w3.org/2001/XMLSchema#string

P2860

Economic costs of diabetes in the U.S. in 2012

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

AMPK: a target for drugs and natural products with effects on both diabetes and cancer

After avandia: the use of antidiabetic drugs in patients with heart failure

Effects of intensive glucose lowering in type 2 diabetes

Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart.

Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006

P2888

s12170-013-0355-4

P304

417-422

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12170-013-0355-4

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24466358

http://www.w3.org/2001/XMLSchema#string

P921

P932

3899937

http://www.w3.org/2001/XMLSchema#string